Evolus (EOLS) Competitors $9.20 -0.01 (-0.11%) Closing price 04:00 PM EasternExtended Trading$9.20 0.00 (-0.05%) As of 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EOLS vs. XENE, BHC, GMTX, APLS, ARWR, TWST, VCEL, KNSA, NAMS, and DNLIShould you be buying Evolus stock or one of its competitors? The main competitors of Evolus include Xenon Pharmaceuticals (XENE), Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), Apellis Pharmaceuticals (APLS), Arrowhead Pharmaceuticals (ARWR), Twist Bioscience (TWST), Vericel (VCEL), Kiniksa Pharmaceuticals International (KNSA), NewAmsterdam Pharma (NAMS), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry. Evolus vs. Its Competitors Xenon Pharmaceuticals Bausch Health Cos Gemini Therapeutics Apellis Pharmaceuticals Arrowhead Pharmaceuticals Twist Bioscience Vericel Kiniksa Pharmaceuticals International NewAmsterdam Pharma Denali Therapeutics Evolus (NASDAQ:EOLS) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk. Do analysts rate EOLS or XENE? Evolus presently has a consensus target price of $23.75, suggesting a potential upside of 158.15%. Xenon Pharmaceuticals has a consensus target price of $54.82, suggesting a potential upside of 70.83%. Given Evolus' higher probable upside, equities research analysts clearly believe Evolus is more favorable than Xenon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evolus 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Xenon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of EOLS or XENE? 90.7% of Evolus shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 6.1% of Evolus shares are held by insiders. Comparatively, 5.5% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is EOLS or XENE more profitable? Xenon Pharmaceuticals has a net margin of 0.00% compared to Evolus' net margin of -20.40%. Xenon Pharmaceuticals' return on equity of -32.44% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Evolus-20.40% -759.04% -20.14% Xenon Pharmaceuticals N/A -32.44%-30.84% Does the media refer more to EOLS or XENE? In the previous week, Xenon Pharmaceuticals had 9 more articles in the media than Evolus. MarketBeat recorded 10 mentions for Xenon Pharmaceuticals and 1 mentions for Evolus. Evolus' average media sentiment score of 1.89 beat Xenon Pharmaceuticals' score of 0.80 indicating that Evolus is being referred to more favorably in the media. Company Overall Sentiment Evolus Very Positive Xenon Pharmaceuticals Positive Which has better valuation and earnings, EOLS or XENE? Evolus has higher revenue and earnings than Xenon Pharmaceuticals. Evolus is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvolus$266.27M2.23-$50.42M-$0.89-10.34Xenon Pharmaceuticals$9.43M261.11-$234.33M-$3.23-9.93 Which has more risk & volatility, EOLS or XENE? Evolus has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. SummaryXenon Pharmaceuticals beats Evolus on 8 of the 15 factors compared between the two stocks. Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EOLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EOLS vs. The Competition Export to ExcelMetricEvolusMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$593.82M$10.48B$5.48B$8.94BDividend YieldN/A2.11%5.38%4.12%P/E Ratio-10.3417.2326.2219.73Price / Sales2.2326.99405.80109.12Price / CashN/A22.8736.4957.06Price / Book102.223.657.925.37Net Income-$50.42M$233.36M$3.15B$248.34M7 Day Performance-4.37%1.73%0.95%1.25%1 Month Performance-1.81%3.03%5.25%5.41%1 Year Performance-16.97%-12.07%32.63%18.06% Evolus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EOLSEvolus4.078 of 5 stars$9.20-0.1%$23.75+158.2%-15.1%$593.82M$266.27M-10.34170Positive NewsXENEXenon Pharmaceuticals3.1226 of 5 stars$31.49-1.7%$54.82+74.1%-19.7%$2.42B$9.43M-9.75210BHCBausch Health Cos3.2193 of 5 stars$6.11-1.1%$7.42+21.4%-4.2%$2.26B$9.73B-55.5520,700GMTXGemini TherapeuticsN/A$51.61+3.0%N/A+20.9%$2.24BN/A-51.6130High Trading VolumeAPLSApellis Pharmaceuticals4.5092 of 5 stars$17.62-0.4%$40.05+127.3%-54.9%$2.21B$775.84M-9.84770News CoverageARWRArrowhead Pharmaceuticals3.9199 of 5 stars$15.51+1.2%$43.71+181.8%-39.2%$2.14B$3.55M-11.08400Positive NewsTWSTTwist Bioscience4.3344 of 5 stars$35.33+2.0%$50.40+42.7%-25.3%$2.12B$347.68M-10.87990VCELVericel2.8966 of 5 stars$41.80-0.5%$61.14+46.3%-7.3%$2.10B$237.22M1,393.80300Positive NewsKNSAKiniksa Pharmaceuticals International3.5563 of 5 stars$28.72+1.0%$38.80+35.1%+48.2%$2.10B$423.24M-114.88220Analyst DowngradeNAMSNewAmsterdam Pharma3.0496 of 5 stars$18.21+1.4%$42.89+135.5%-5.7%$2.04B$45.56M-9.694DNLIDenali Therapeutics4.5504 of 5 stars$13.62-1.9%$33.71+147.5%-39.8%$1.98B$330.53M-5.10430News CoverageGap Up Related Companies and Tools Related Companies Xenon Pharmaceuticals Competitors Bausch Health Cos Competitors Gemini Therapeutics Competitors Apellis Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors Twist Bioscience Competitors Vericel Competitors Kiniksa Pharmaceuticals International Competitors NewAmsterdam Pharma Competitors Denali Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EOLS) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold Shock (insane new prediction)World Gold Council reports: "No sign" of this catalyst slowing A whopping 73% of Americans report they're "...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
